The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Carl Zeiss Meditec; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Lilly; MSD; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sandoz; Seagen; Tesaro; Teva
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Genomic Health
Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.
 
Oleg Gluz
Consulting or Advisory Role - Amgen; Genomic Health; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; Roche
 
Ulrike Nitz
Honoraria - Agendia; Amgen; Celgene; Genomic Health; Novartis; Pfizer; Roche; Teva
Consulting or Advisory Role - Genomic Health; Roche
Research Funding - Genomic Health (Inst)
Travel, Accommodations, Expenses - Genomic Health; Pfizer; Roche
 
Matthias Christgen
No Relationships to Disclose
 
Michael Braun
Honoraria - AstraZeneca; Exact Sciences; Novartis; Pfizer; Roche; Teva
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Novartis; Puma Biotechnology; Roche
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Medac; Novartis; Roche
 
Kerstin Luedtke-Heckenkamp
Honoraria - AstraZeneca; Eisai Germany; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Merck Serono; Novartis; Roche Pharma AG
Travel, Accommodations, Expenses - Celgene/Bristol-Myers Squibb; Novartis; Pfizer; Roche Pharma AG
 
Maren Darsow
No Relationships to Disclose
 
Helmut Forstbauer
No Relationships to Disclose
 
Jochem Potenberg
No Relationships to Disclose
 
Christoph Uleer
No Relationships to Disclose
 
Eva-Maria Grischke
No Relationships to Disclose
 
Bahriye Aktas
Honoraria - AstraZeneca; Lilly; MSD; Novartis; Pfizer; PharmaMar; Promedicis; Roche
 
Claudia Schumacher
No Relationships to Disclose
 
Christine zu Eulenburg
No Relationships to Disclose
 
Katarzyna Jozwiak
No Relationships to Disclose
 
Ronald E. Kates
No Relationships to Disclose
 
Monika Graeser
No Relationships to Disclose
 
Rachel Wuerstlein
No Relationships to Disclose
 
Hans Heinrich Kreipe
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Roche
 
Sherko Kuemmel
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche/Genentech; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche; Sonoscape
(OPTIONAL) Uncompensated Relationships - West German Study Group
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)